These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 30496460)

  • 21. Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs.
    Zuur MA; Pasipanodya JG; van Soolingen D; van der Werf TS; Gumbo T; Alffenaar JC
    Clin Infect Dis; 2018 Nov; 67(11):1743-1749. PubMed ID: 29697766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis.
    Srivastava S; Modongo C; Siyambalapitiyage Dona CW; Pasipanodya JG; Deshpande D; Gumbo T
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5922-7. PubMed ID: 27458215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Using of the Sensititre MycoTB Plate Method for the Detection of Anti-tuberculous Drug Susceptibility of Rifampin Resistant Mycobacterium tuberculosis Complex Isolates].
    Ceyhan İ; Vezir S
    Mikrobiyol Bul; 2020 Apr; 54(2):211-222. PubMed ID: 32723277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.
    Mpagama SG; Ndusilo N; Stroup S; Kumburu H; Peloquin CA; Gratz J; Houpt ER; Kibiki GS; Heysell SK
    Antimicrob Agents Chemother; 2014; 58(2):782-8. PubMed ID: 24247125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.
    Davies Forsman L; Giske CG; Bruchfeld J; Schön T; Juréen P; Ängeby K
    Int J Mycobacteriol; 2015 Mar; 4 Suppl 1():80-1. PubMed ID: 27128620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Repurposing Cefazolin-Avibactam for the Treatment of Drug Resistant
    Srivastava S; Gumbo T; Thomas T
    Front Pharmacol; 2021; 12():776969. PubMed ID: 34744753
    [No Abstract]   [Full Text] [Related]  

  • 27. Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.
    Pasipanodya JG; Nuermberger E; Romero K; Hanna D; Gumbo T
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S10-7. PubMed ID: 26224767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks.
    Srivastava S; Deshpande D; Pasipanodya J; Nuermberger E; Swaminathan S; Gumbo T
    Clin Infect Dis; 2016 Nov; 63(suppl 3):S102-S109. PubMed ID: 27742641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Semimechanistic Model of the Bactericidal Activity of High-Dose Isoniazid against Multidrug-Resistant Tuberculosis: Results from a Randomized Clinical Trial.
    Gausi K; Ignatius EH; Sun X; Kim S; Moran L; Wiesner L; von Groote-Bidlingmaier F; Hafner R; Donahue K; Vanker N; Rosenkranz SL; Swindells S; Diacon AH; Nuermberger EL; Dooley KE; Denti P
    Am J Respir Crit Care Med; 2021 Dec; 204(11):1327-1335. PubMed ID: 34403326
    [No Abstract]   [Full Text] [Related]  

  • 30. Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium.
    Deshpande D; Srivastava S; Meek C; Leff R; Gumbo T
    Antimicrob Agents Chemother; 2010 May; 54(5):1728-33. PubMed ID: 20231389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Linezolid-based Regimens for Multidrug-resistant Tuberculosis (TB): A Systematic Review to Establish or Revise the Current Recommended Dose for TB Treatment.
    Bolhuis MS; Akkerman OW; Sturkenboom MGG; Ghimire S; Srivastava S; Gumbo T; Alffenaar JC
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S327-S335. PubMed ID: 30496467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimizing dosing of the cycloserine pro-drug terizidone in children with rifampicin-resistant tuberculosis.
    van der Laan LE; Garcia-Prats AJ; McIlleron H; Abdelwahab MT; Winckler JL; Draper HR; Wiesner L; Schaaf HS; Hesseling AC; Denti P
    Antimicrob Agents Chemother; 2023 Dec; 67(12):e0061123. PubMed ID: 37971239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Application of quantitative second-line drug susceptibility testing at a multidrug-resistant tuberculosis hospital in Tanzania.
    Mpagama SG; Houpt ER; Stroup S; Kumburu H; Gratz J; Kibiki GS; Heysell SK
    BMC Infect Dis; 2013 Sep; 13():432. PubMed ID: 24034230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.
    Bouton TC; Phillips PPJ; Mitnick CD; Peloquin CA; Eisenach K; Patientia RF; Lecca L; Gotuzzo E; Gandhi NR; Butler D; Diacon AH; Martel B; Santillan J; Hunt KR; Vargas D; von Groote-Bidlingmaier F; Seas C; Dianis N; Moreno-Martinez A; Horsburgh CR
    Trials; 2017 Nov; 18(1):563. PubMed ID: 29178937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Sterilizing Effect of Intermittent Tedizolid for Pulmonary Tuberculosis.
    Srivastava S; Deshpande D; Nuermberger E; Lee PS; Cirrincione K; Dheda K; Gumbo T
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S336-S341. PubMed ID: 30496463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Agreement of Middle brook 7H10 with Lowenstein Jensen and accuracy of the Sensititre MYCOTB plate using either method as a reference standard for Mycobacterium tuberculosis first line drug susceptibility testing.
    Ssengooba W; Nakayita G; Namaganda CC; Joloba ML
    PLoS One; 2018; 13(6):e0199638. PubMed ID: 29953491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Steady state pharmacokinetics of cycloserine in patients on terizidone for multidrug-resistant tuberculosis.
    Court R; Wiesner L; Stewart A; de Vries N; Harding J; Maartens G; Gumbo T; McIlleron H
    Int J Tuberc Lung Dis; 2018 Jan; 22(1):30-33. PubMed ID: 29297422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection.
    Al-Shaer MH; Alghamdi WA; Alsultan A; An G; Ahmed S; Alkabab Y; Banu S; Barbakadze K; Houpt E; Kipiani M; Mikiashvili L; Cegielski JP; Kempker RR; Heysell SK; Peloquin CA
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.
    Gumbo T; Pasipanodya JG; Nuermberger E; Romero K; Hanna D
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S18-24. PubMed ID: 26224768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of Second-Line Anti-Tubercular Drugs.
    Ramachandran G
    Indian J Pediatr; 2019 Aug; 86(8):714-716. PubMed ID: 30924070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.